KK
SPRY icon

KLP Kapitalforvaltning’s ARS Pharmaceuticals SPRY Stock Holding History

KLP Kapitalforvaltning’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.9K Hold
11,600
– – ﹤0.01% 2091
2026
Q1 		$93.1K Hold
11,600
– – ﹤0.01% 2068
2025
Q4 		$135K Hold
11,600
– – ﹤0.01% 1979
2025
Q3 		$117K Hold
11,600
– – ﹤0.01% 2022
2025
Q2 		$202K Buy
11,600
+4,700
+68% +$67.8K ﹤0.01% 1780
2025
Q1 		$86.8K Hold
6,900
– – ﹤0.01% 2075
2024
Q4 		$72.8K Buy
+6,900
New +$96.6K ﹤0.01% 2182

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

KLP Kapitalforvaltning's SPRY Position: Q2 2026 in Review

KLP Kapitalforvaltning held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 11,600 shares worth $92.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

KLP Kapitalforvaltning first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $202K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • KLP Kapitalforvaltning held 11,600 shares of ARS Pharmaceuticals worth $92.9K as of Q2 2026.
  • KLP Kapitalforvaltning left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #2091 holding.
  • KLP Kapitalforvaltning first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's ARS Pharmaceuticals position peaked at $202K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.